Trump Administration Takes Action on Medicare Drug Price Negotiation Loophole
The Trump administration has announced measures aimed at addressing a loophole in Medicare drug price negotiations, which could affect costs for beneficiaries and pharmaceutical companies.
Editorial Staff
1 min read
Updated about 19 hours ago
On June 12, 2026, the Trump administration revealed its intention to tackle a loophole in the Medicare drug price negotiation process.
This policy is designed to enhance negotiations and potentially lower costs for Medicare beneficiaries.
The changes may also have implications for pharmaceutical companies, as the administration seeks to improve the affordability of medications.